Casdatifan, a HIF-2α inhibitor, shows early clinical activity and good tolerance in patients with previously treated clear ...

A personalized vaccine demonstrated the potential to induce long-lasting immune response among people with advanced kidney ...

Lung cancer remains one of the leading causes of cancer-related mortality, with lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) representing the most prevalent subtypes of non-small ...

Inceptor Bio, a clinical-stage biotechnology company pioneering next-generation cell therapies, today announced that the first patient has been dosed in the clinical trial of IB-T101, the company's ...

Development of an ex-vivo platform to model immunotherapy in kidney cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers Symposium. This abstract does not include a full ...

Local definitive therapy (LDT) utilization patterns and outcomes in chromophobe renal cell carcinoma (chRCC) with metachronous metastasis: A multi-institution study. This is an ASCO Meeting Abstract ...

US-based biotechnology company Inceptor Bio has dosed the first subject in the investigator-initiated trial of its lead ...

The FDA granted priority review to TLX250-CDx for clear cell renal cell carcinoma imaging, with a PDUFA date of August 27, ...

of Northwestern University as a second site in a clinical trial combining the Company’s proprietary compound LB-100 with GSK’s Dostarlimab to treat ovarian clear cell cancer. Emily M.